Amicus Therapeutics, Inc. (FOLD)
NASDAQ: FOLD · Real-Time Price · USD
5.99
-0.09 (-1.56%)
At close: May 9, 2025, 4:00 PM
6.09
+0.10 (1.75%)
After-hours: May 9, 2025, 7:02 PM EDT
Company Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally.
The company’s commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease.
It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold.
Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Amicus Therapeutics, Inc.
| Country | United States |
| Founded | 2002 |
| IPO Date | May 31, 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 499 |
| CEO | Bradley Campbell |
Contact Details
Address: 47 Hulfish Street Princeton, New Jersey 08542 United States | |
| Phone | 609 662 2000 |
| Website | amicusrx.com |
Stock Details
| Ticker Symbol | FOLD |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001178879 |
| CUSIP Number | 03152W109 |
| ISIN Number | US03152W1099 |
| Employer ID | 20-0422823 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Bradley L. Campbell M.B.A. | Chief Executive Officer, President and Director |
| Simon Nicolas Reade Harford | Chief Financial Officer |
| Ellen S. Rosenberg J.D. | Chief Legal Officer and Corporate Secretary |
| David M. Clark | Chief People Officer |
| Dr. Jeffrey P. Castelli Ph.D. | Chief Development Officer |
| Dr. Jill Weimer Ph.D. | Chief Science Officer |
| Andrew Faughnan | Vice President of Investor Relations |
| Patrik S. Florencio Esq. | Global Chief Compliance and Risk Officer |
| Diana Moore | Head of Global Corporate Communications |
| Jayne C. Gershkowitz | Chief Patient Advocate |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 9, 2025 | SCHEDULE 13G/A | Filing |
| May 1, 2025 | 10-Q | Quarterly Report |
| May 1, 2025 | 8-K | Current Report |
| May 1, 2025 | 8-K | Current Report |
| Apr 24, 2025 | ARS | Filing |
| Apr 24, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 24, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 23, 2025 | SCHEDULE 13G/A | Filing |
| Feb 21, 2025 | 8-K | Current Report |
| Feb 21, 2025 | 424B5 | Filing |